Related Experiment Video
Updated: May 16, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Missing a trick? Bupropion for the pharmacological treatment of depression in the UK
Michael Browning1,2, Philip J Cowen1,2
1Department of Psychiatry, University of Oxford, Oxford, UK.
Abstract:
Bupropion is not licensed as an antidepressant in the UK, limiting its use. We highlight bupropion's distinct pharmacological profile and its potential benefits in treatment-resistant depression and people experiencing selective serotonin reuptake inhibitor-induced sexual dysfunction. The National Health Service repurposing medicines programme could improve equity of access for UK patients.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Mania and Antimanic Drugs: Overview
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

